The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening

The cblC type of combined methylmalonic acidemia and homocystinuria, an inherited disorder with variable phenotypes, is included in newborn screening (NBS) programs at multiple newborn screening centers in China. The present study aimed to investigate the long-term clinical benefits of screening ind...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in genetics Vol. 13; p. 805599
Main Authors Ling, Shiying, Wu, Shengnan, Shuai, Ruixue, Yu, Yue, Qiu, Wenjuan, Wei, Haiyan, Yang, Chiju, Xu, Peng, Zou, Hui, Feng, Jizhen, Niu, Tingting, Hu, Haili, Zhang, Huiwen, Liang, Lili, Lu, Deyun, Gong, Zhuwen, Zhan, Xia, Ji, Wenjun, Gu, Xuefan, Han, Lianshu
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 15.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The cblC type of combined methylmalonic acidemia and homocystinuria, an inherited disorder with variable phenotypes, is included in newborn screening (NBS) programs at multiple newborn screening centers in China. The present study aimed to investigate the long-term clinical benefits of screening individual. A national, retrospective multi-center study of infants with confirmed cblC defect identified by NBS between 2004 and 2020 was conducted. We collected a large cohort of 538 patients and investigated their clinical data in detail, including disease onset, biochemical metabolites, and gene variation, and explored different factors on the prognosis. The long-term outcomes of all patients were evaluated, representing 44.6% for poor outcomes. In our comparison of patients with already occurring clinical signs before treatment to asymptomatic ones, the incidence of intellectual impairment, movement disorders, ocular complications, hydrocephalus, and death were significantly different ( < 0.01). The presence of disease onset [Odd ratio (OR) 12.39, 95% CI 5.15-29.81; = 0.000], variants of c.609G>A (OR 2.55, 95% CI 1.49-4.35; = 0.001), and c.567dupT (OR 2.28, 95% CI 1.03-5.05; = 0.042) were independently associated with poor outcomes, especially for neurodevelopmental deterioration. NBS, avoiding major disease-related events and allowing an earlier treatment initiation, appeared to have protective effects on the prognosis of infants with cblC defect.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work
This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics
Harvey L. Levy, Boston Children’s Hospital and Harvard Medical School, United States
Edited by: Carmen Gherasim, University of Michigan, United States
Reviewed by: Jennifer Sloan, National Human Genome Research Institute (NHGRI), United States
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2022.805599